Phosphodiesterase-4 inhibitors have demonstrated clinical efficacy in AD patients by enhancing anti-inflammatory cytokine production (e. g., IL-10) while concurrently suppressing pro-inflammatory mediators (IL-4, IL-13, IL-22) and chemokine synthesis139,.140. The gene discussed is IL13; the disease is Alzheimer disease.